Table of Contents
Chemotherapy Research and Practice
Volume 2012 (2012), Article ID 838509, 8 pages
http://dx.doi.org/10.1155/2012/838509
Review Article

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia

Received 16 December 2011; Accepted 7 March 2012

Academic Editor: Enzo Bonmassar

Copyright © 2012 Linda Mileshkin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalized treatment for people with certain tumours. The epidermal growth factor receptor (EGFR) and K-ras are two such targets that can help classify tumours on a molecular basis and guide treatment decisions. However, there are still questions about how best to implement new molecular tests like these to characterize tumours in clinical practice. Potential obstacles include availability of good quality tissue specimens, access to the right test, and consensus about interpretation, funding, and availability. In this paper, we review these issues, by discussing these two examples in detail and suggest some actions for addressing potential barriers.